Ortho-Clinical Diagnostics Licenses Intrinsic Bioprobes' Markers | GenomeWeb

NEW YORK (GenomeWeb News) – Intrinsic Bioprobes, a private clinical diagnostics developer, said today that it has licensed two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, a Johnson & Johnson company.

The blood-circulating proteins covered under the license, which were discovered using Intrinsic's mass spectrometry-based technology, have been linked with the presence of pre-diabetes and type 2 diabetes, the Tempe, Ariz.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.